Premium
Successful treatment with recombinant factor VIIa of therapy‐resistant severe bleeding in a patient with acquired von Willebrand disease
Author(s) -
Friederich Philip W.,
Wever Peter C.,
Briët Ernest,
Doorenbos Cornelis J.,
Levi Marcel
Publication year - 2001
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.1060
Subject(s) - desmopressin , medicine , von willebrand disease , von willebrand factor , recombinant factor viia , tranexamic acid , hemostasis , coagulopathy , surgery , gastroenterology , platelet , blood loss
We describe an elderly man who presented with life‐threatening hematuria and gastrointestinal bleeding caused by acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance (MGUS). Standard therapy with desmopressin, von Willebrand factor‐containing factor VIII concentrate, tranexamic acid, and immunoglobulin failed to achieve adequate hemostasis. However, treatment with recombinant activated factor VII (rFVIIa) arrested the bleeding completely. Since acquired von Willebrand disease can lead to life‐threatening hemorrhage, clinicians should consider rFVIIa as an effective treatment option if standard therapy fails. Am. J. Hematol. 66:292–294, 2001. © 2001 Wiley‐Liss, Inc.